Beard Vivienne K, Bedard Angela C, Nuk Jennifer, Lee Petra W C, Hong Quan, Bedard James E J, Sun Sophie, Schrader Kasmintan A
Department of Biology (Beard, Lee, J.E.J. Bedard), University of the Fraser Valley, Abbotsford, BC; Hereditary Cancer Program (A.C. Bedard, Nuk, Hong, Sun, Schrader), BC Cancer; Division of Medical Oncology (Sun), University of British Columbia; Department of Molecular Oncology (Schrader), BC Cancer; Department of Medical Genetics (Schrader), University of British Columbia, Vancouver, BC.
Department of Biology (Beard, Lee, J.E.J. Bedard), University of the Fraser Valley, Abbotsford, BC; Hereditary Cancer Program (A.C. Bedard, Nuk, Hong, Sun, Schrader), BC Cancer; Division of Medical Oncology (Sun), University of British Columbia; Department of Molecular Oncology (Schrader), BC Cancer; Department of Medical Genetics (Schrader), University of British Columbia, Vancouver, BC
CMAJ Open. 2020 Oct 19;8(4):E637-E642. doi: 10.9778/cmajo.20190167. Print 2020 Oct-Dec.
Genetic testing in families with hereditary cancer enables identification of people most likely to benefit from intensive screening and preventive measures; however, the uptake of testing in relatives (known as cascade carrier testing) for hereditary colorectal cancer syndromes has been shown to be low. Our objective was to report rates of familial testing for hereditary colorectal cancer syndromes in a publicly funded hereditary cancer clinic in Canada.
A cross-sectional retrospective database review was used to determine testing uptake between 1997 and 2016 for families served by the provincial Hereditary Cancer Program for British Columbia and Yukon. Analyses were conducted for genes associated with syndromes with an increased risk for colorectal cancer, including Lynch syndrome (, , , and ) and familial adenomatous polyposis (), and for additional moderate- to high-penetrance genes (, , , , and ). Descriptive statistics were used and all analyses were 2-tailed.
The study cohort included 245 index patients, with carrier testing performed in 382 relatives. The mean age at family member testing was 41.2 years, and most (61.0%) of the family members who underwent testing were women. The median time between disclosure of index cases and their family member's results was 8.3 months. Among eligible first-degree relatives, 32.6% (268/821) underwent testing in BC. Of 67 cancer diagnoses in family members, most (62.7%) occurred before genetic testing.
A substantial proportion of people at risk for hereditary colorectal cancer do not undergo genetic testing. This gap highlights the need to explore barriers to testing and to consider interventions to promote uptake; more aggressive efforts by hereditary cancer programs are needed to reach this highest risk population.
对遗传性癌症家族进行基因检测能够确定最有可能从强化筛查和预防措施中获益的人群;然而,遗传性结直肠癌综合征亲属(即所谓的级联携带者检测)的检测率一直很低。我们的目的是报告加拿大一家由公共资金资助的遗传性癌症诊所中遗传性结直肠癌综合征家族检测的比率。
采用横断面回顾性数据库审查,以确定1997年至2016年期间不列颠哥伦比亚省和育空地区省级遗传性癌症项目所服务家庭的检测接受情况。对与结直肠癌风险增加的综合征相关的基因进行了分析,包括林奇综合征(、、、和)和家族性腺瘤性息肉病(),以及其他中度至高度 penetrance 基因(、、、、和)。使用描述性统计,所有分析均为双侧检验。
研究队列包括245名索引患者,对382名亲属进行了携带者检测。家庭成员检测时的平均年龄为41.2岁,接受检测的家庭成员中大多数(61.0%)为女性。索引病例披露与其家庭成员结果之间的中位时间为8.3个月。在符合条件的一级亲属中,32.6%(268/821)在不列颠哥伦比亚省接受了检测。在家庭成员的67例癌症诊断中,大多数(62.7%)发生在基因检测之前。
相当一部分有遗传性结直肠癌风险的人未接受基因检测。这一差距凸显了探索检测障碍并考虑促进检测接受的干预措施的必要性;遗传性癌症项目需要做出更积极的努力,以覆盖这一最高风险人群。